Applications of (4-Chlorophenyl)(4-Piperidyl)Methanone Hydrochloride in Industrial Manufacturing

As the direct manufacturer of (4-Chlorophenyl)(4-Piperidyl)Methanone Hydrochloride, we supply this advanced intermediate for critical syntheses within regulated sectors. Each downstream field presents specific demands for compliance, dosing, and process, as outlined below.

1. Active Pharmaceutical Ingredient (API) Synthesis – Antipsychotic Drug Manufacturing

Pharmaceutical companies employ this compound as a highly selective intermediate when developing essential antipsychotic medications. Our material integrates at the arylation stage of piperidine-based API synthesis, dictated by stringent GMP protocols. Customization of use ratios closely follows the reaction yield demands for target molecules, impacting the purity and performance of the designated finished medicines. Robust documentation supports each shipment to meet regional and international pharmaceutical standards.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU EudraLex Volume 4, Part II (GMP for APIs)
• US FDA 21 CFR Part 210/211: cGMP for Finished Pharmaceuticals
• Chinese Pharmacopoeia (ChP), as relevant for domestic supply

Typical usage ratio

• 0.95–1.15 molar equivalent relative to piperidine-based precursor, adjusted to balance purity and yield in scale-up

Downstream process integration

• Material loaded into condensation or arylation reaction vessels during intermediate formation of the final API; used prior to purification and salt formation steps

Final product types

• Quetiapine fumarate
• Other novel piperidine-based antipsychotics

2. CNS-Active Compound Intermediate for Neuropharmaceutical R&D

Research organizations and clinical trial supply chains utilize our intermediate for synthesizing innovative central nervous system (CNS) active molecules. Progression of early-stage compounds typically requires tight control on impurity profiles, where our product supports the chlorinated arylation step during lead optimization and batch validation for IND-enabling toxicology. Supply documentation aligns with API research standards and ensures full traceability into pilot and early market batches.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• ISO 9001:2015 Quality Management System
• US Drug Supply Chain Security Act (DSCSA) - transparency for investigational materials

Typical usage ratio

• 1.0–1.2 molar equivalents per target molecule, modified per project protocol after analytical monitoring

Downstream process integration

• Fed incrementally into multi-step synthetic schemes; introduced during the halogenation and cyclization routes for CNS-active research molecules

Final product types

• Clinical trial samples for CNS disorders
• Early-stage neuropharmaceutical candidates for regulatory submission

3. Advanced Intermediate for Agrochemical Development

Major agrochemical producers introduce this specialty compound into the construction of selective piperidine-based crop protection agents. Adherence to global and regional agchem registration standards is essential. Usage ratios depend on target molecule structure and process efficiency, while application sequence varies based on the crop protection product’s desired mode of action. Our material supports industrial-scale routes for commercial plant protection agents, enabling accurate process validation and regulatory submission.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP) for pesticide intermediates
• REACH Regulation (EC) No 1907/2006—registration for supply in EU markets
• US EPA Laws for active ingredient intermediates and manufacturing practices

Typical usage ratio

• 0.9–1.1 molar equivalence, fine-tuned according to synthetic yield, impurity content, and downstream purification setup

Downstream process integration

• Added to ring-building stages of fungicide or herbicide intermediate synthesis, immediately prior to coupling or final functionalization

Final product types

• Commercial piperidine-derived fungicides
• Herbicidal products requiring advanced aromatic ring systems

4. Custom Synthesis for Contract Development and Manufacturing Organizations (CDMO) Projects

CDMO partners engage our facility for batch production of this intermediate under exclusive synthesis contracts, supporting client-specific compound development for late-stage preclinical or commercial launches. Custom process development often focuses on impurity reduction and scalable, validated batch production in line with client submissions to regulatory agencies. Comprehensive process validation, batch records, and analytical confirmations accompany each lot.

Industry compliance standards

• US FDA 21 CFR Part 211 and ICH Q7 for contracted cGMP manufacturing
• MHRA (UK Medicines & Healthcare products Regulatory Agency) GMP rules for pharmaceutical outsourcing
• ISO 13485:2016 for medical compound intermediates where applicable

Typical usage ratio

• Adjusted per client-originated protocol, commonly 0.95–1.10 molar equivalents, taking full batch traceability and analytical release data into account

Downstream process integration

• Delivered as a stage-specific intermediate for direct integration with custom, proprietary downstream transformations

Final product types

• Late-phase clinical or commercial piperidine-based APIs
• Specialty pharmaceutical compounds for global market entry

5. Fine Chemical Intermediate for Chemical Reference Standard Production

Accredited laboratories and chemical reference standard providers use this material in the preparation of analytical reference compounds needed for quality control and regulatory testing across pharmaceutical environments. Strict batch consistency, low impurity content, and documented origin are required to ensure compliance with compendial standards and facilitate accurate instrument calibration and batch release analytics.

Industry compliance standards

• USP (United States Pharmacopeia) / EP (European Pharmacopoeia) Reference Standard quality parameters
• ISO/IEC 17025 Laboratory Accreditation Requirements

Typical usage ratio

• Precisely matched to the stoichiometry of analytical compound preparation, typically 1:1 or 1.05 molar equivalents per calibration target

Downstream process integration

• Processed at the reference compound synthesis stage; follows highly controlled purification and analytical verification procedures

Final product types

• Certified pharmaceutical reference materials
• Analytical standards for regulatory QC laboratories

6. Intermediate for Advanced Organic Synthesis in Academic Research

University research centers and advanced organic chemistry laboratories apply the compound as a specialized intermediate for the synthesis of novel heterocyclic scaffolds. Typical research work involves targeted modification, SAR studies, or the investigation of bioactive analogues. Each project establishes its own purity and usage parameters to support peer-reviewed publication, intellectual property generation, or technology transfer.

Industry compliance standards

• Institutional chemical safety management protocols
• Material Transfer Agreements (MTA) and academic-use guidelines

Typical usage ratio

• Ranged from 0.8 to 1.2 molar equivalents depending on research goals, reactivity, and planned analytical study endpoints

Downstream process integration

• Used during multi-step synthetic sequence as a building block for heterocyclic core construction, prior to downstream derivatization or structure-activity modification

Final product types

• Novel research intermediates
• SAR analogues and lead compound libraries